Humana Sells Minority Stake in Hospice Provider Gentiva

• The $900 million sale is not expected to impact Humana's 2026 earnings, with proceeds designated for general corporate purposes
• Gentiva operates more than 430 hospice care locations across 35 states, providing services for seriously ill patients
• Humana previously sold a majority stake in Kindred at Home's hospice and personal care units to private equity firm Clayton, Dubilier & Rice in 2022

Humana Divests Minority Stake in Gentiva for $900 Million

Humana announced Wednesday it has agreed to sell substantially all of its minority stake in Gentiva, a hospice and palliative care provider, to a group of investors in a deal valued at approximately $900 million. The healthcare insurer did not disclose additional financial terms or identify the buyer group.

Transaction Details:

• Deal value: ~$900 million
• Expected closing: Q3 2026
• Subject to regulatory approvals and customary closing conditions
• Proceeds will be used for general corporate purposes
• No expected impact on 2026 earnings

Background:

Humana's stake in Gentiva originated from its 2021 acquisition of Kindred at Home. Following that deal, Humana indicated plans to divest non-core hospice and personal care assets. In 2022, the company sold a majority stake in Kindred at Home's hospice and personal care divisions to private equity firm Clayton, Dubilier & Rice, retaining only a minority position.

About Gentiva:

The company operates more than 430 locations across 35 states, providing hospice care and support services for seriously ill patients.

Market Implications:

This divestiture represents Humana's continued strategic focus on core business operations while optimizing its portfolio. The sale allows the company to monetize a non-core asset while maintaining financial stability, with no anticipated earnings impact. The transaction aligns with Humana's broader strategy to streamline operations following previous M&A activity in the home healthcare sector. The deal's 2026 timeline provides ample opportunity for regulatory review in the healthcare services space.